Mitochondrial dynamics — the coordinated cycles of fission, fusion, biogenesis, and mitophagy — are progressively disrupted with chronological age. The resulting phenotypes include accumulation of damaged organelles, loss of mitochondrial membrane potential, increased reactive oxygen species output, and progressive impairment of oxidative phosphorylation efficiency. Across model systems, these changes track with declines in metabolic flexibility, insulin sensitivity, and exercise capacity.
The experimental challenge is that no single model recapitulates all relevant aspects of age-related mitochondrial dysfunction. Cell-culture systems reveal molecular machinery (DRP1, MFN1/2, OPA1, PINK1/PARKIN) but lack the systemic metabolic context. Murine aging models capture organism-level changes but with limited translatability to human biology. Human primary myocytes from aged donors retain donor-age phenotypes, providing a useful intermediate system for assessing whether candidate interventions can reverse age-associated mitochondrial decline.
Interventions under active investigation include NAD+ precursors (which restore the substrate pool for sirtuin-mediated mitochondrial biogenesis), urolithin A (which selectively induces mitophagy via the PINK1/PARKIN axis), MOTS-c and other mitochondrial-derived peptides, and rapamycin and analogs targeting mTOR-dependent mitochondrial dynamics. The most rigorous comparative work is just beginning to emerge, and the field is moving toward composite-endpoint assessments rather than single-marker measurements.